These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 14684678)

  • 21. The cardiovascular burden of end-stage renal disease patients.
    Cianciolo G; Donati G; La Manna G; Ferri A; Cuna V; Ubaldi G; Corsini S; Lanci N; Colì L; Stefoni S
    Minerva Urol Nefrol; 2010 Mar; 62(1):51-66. PubMed ID: 20424570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective.
    Zoccali C
    Kidney Int; 2006 Jul; 70(1):26-33. PubMed ID: 16723985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Arginine, arginine analogs and nitric oxide production in chronic kidney disease.
    Baylis C
    Nat Clin Pract Nephrol; 2006 Apr; 2(4):209-20. PubMed ID: 16932427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Why do patients with kidney diseases end up with a heart of stone? Disturbances in calcium-phosphate balance and chronic inflammation important causes].
    Martola L; Elinder CG; Stenvinkel P
    Lakartidningen; 2003 Dec; 100(50):4180-3. PubMed ID: 14717005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxidative stress and asymmetric dimethylarginine are associated with cardiovascular complications in hemodialysis patients: improvements by L-arginine intake.
    El-Mesallamy HO; Abdel Hamid SG; Gad MZ
    Kidney Blood Press Res; 2008; 31(3):189-95. PubMed ID: 18511874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move.
    Zoccali C
    J Hypertens; 2006 Apr; 24(4):611-9. PubMed ID: 16531785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of asymmetric dimethylarginine and endothelial dysfunction.
    Böger RH
    Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum Asymmetric and Symmetric Dimethylarginine and Morbidity and Mortality in Hemodialysis Patients.
    Shafi T; Hostetter TH; Meyer TW; Hwang S; Hai X; Melamed ML; Banerjee T; Coresh J; Powe NR
    Am J Kidney Dis; 2017 Jul; 70(1):48-58. PubMed ID: 28089476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical significance of asymmetric dimethylarginine.
    Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
    Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.
    Emrich IE; Zawada AM; Martens-Lobenhoffer J; Fliser D; Wagenpfeil S; Heine GH; Bode-Böger SM
    Clin Res Cardiol; 2018 Mar; 107(3):201-213. PubMed ID: 29101459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine.
    Blackwell S
    Ann Clin Biochem; 2010 Jan; 47(Pt 1):17-28. PubMed ID: 19940201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?
    Zoccali C; Kielstein JT
    Curr Opin Nephrol Hypertens; 2006 May; 15(3):314-20. PubMed ID: 16609301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
    Siroká R; Cibulka R; Rajdl D; Racek J
    Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients.
    Tripepi G; Mattace Raso F; Sijbrands E; Seck MS; Maas R; Boger R; Witteman J; Rapisarda F; Malatino L; Mallamaci F; Zoccali C
    Clin J Am Soc Nephrol; 2011 Jul; 6(7):1714-21. PubMed ID: 21642364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism.
    Wilcken DE; Sim AS; Wang J; Wang XL
    Mol Genet Metab; 2007 Aug; 91(4):309-17; discussion 308. PubMed ID: 17560156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal disease as a risk factor for cardiovascular disease.
    Luft FC
    Basic Res Cardiol; 2000; 95 Suppl 1():I72-6. PubMed ID: 11192357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery.
    Maas R; Dentz L; Schwedhelm E; Thoms W; Kuss O; Hiltmeyer N; Haddad M; Klöss T; Standl T; Böger RH
    Crit Care Med; 2007 Aug; 35(8):1876-81. PubMed ID: 17581491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Asymmetric dimethylarginine, vascular calcifications and parathyroid hormone serum levels in hemodialysis patients.
    Coen G; Mantella D; Sardella D; Beraldi MP; Ferrari I; Pierantozzi A; Lippi B; Di Giulio S
    J Nephrol; 2009; 22(5):616-22. PubMed ID: 19809994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relations between concentrations of asymmetric dimethylarginine and neopterin as potential risk factors for cardiovascular diseases in haemodialysis-treated patients.
    Avci E; Coskun S; Cakir E; Kurt Y; Ozgur Akgul E; Bilgi C
    Ren Fail; 2008; 30(8):784-90. PubMed ID: 18791952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
    Richir MC; Bouwman RH; Teerlink T; Siroen MP; de Vries TP; van Leeuwen PA
    JPEN J Parenter Enteral Nutr; 2008; 32(6):613-21. PubMed ID: 18974239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.